Chessy Marie Dintruff, | |
1391 Broad Ave Ste A, Gulfport, MS 39501-2419 | |
(228) 863-8868 | |
Not Available |
Full Name | Chessy Marie Dintruff |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 1391 Broad Ave Ste A, Gulfport, Mississippi |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740816834 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | PA00509 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
Chessy Marie Dintruff, Po Box 1810, Gulfport, MS 39502-1810 Ph: (228) 575-1194 | Chessy Marie Dintruff, 1391 Broad Ave Ste A, Gulfport, MS 39501-2419 Ph: (228) 863-8868 |
News Archive
Digestive Care, Inc. (DCI) announced today that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) and has moved closer to obtaining approval of its New Drug Application (NDA) for PANCRECARB((R) )(pancrelipase) used for the treatment of Exocrine Pancreatic Insufficiency.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
Perrigo Company today announced results for its third quarter ended March 30, 2013.Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with our performance, as the team delivered all-time record quarterly revenue and adjusted diluted earnings per share.
The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded $4 million in the form of two research grants from GlaxoSmithKline (GSK) to develop studies to scientifically evaluate and define GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. Previous research has indicated that BRAF mutations are strong targets for therapies in the treatment of advanced melanoma.
› Verified 1 days ago
Mrs. Amanda Leblanc Harris, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 11295 E Taylor Rd, Gulfport, MS 39503 Phone: 228-864-3300 Fax: 228-864-3333 | |
Wesley Armstrong, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 15200 Community Rd, Gulfport, MS 39503 Phone: 228-575-7000 | |
Jessica Lofton, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 5502 Marvin Shields Blvd, Gulfport, MS 39501 Phone: 228-822-5770 | |
Regal Cox, CST, CSFA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 4500 13th St, Gulfport, MS 39501 Phone: 228-867-4000 | |
Kassie Stafford, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 11295 E Taylor Rd, Gulfport, MS 39503 Phone: 228-864-3300 Fax: 228-864-3333 | |
John Miyakawa, PHYSICIAN ASSISTANT Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 12337 Ashley Dr, Suite F, Gulfport, MS 39503 Phone: 228-365-6932 | |
Thuy T Tran, P.A. Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 431 Security Sq, Gulfport, MS 39507 Phone: 985-643-4575 Fax: 833-222-4520 |